The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity
- PMID: 1931960
- DOI: 10.1021/bi00107a002
The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity
Abstract
Tissue factor pathway inhibitor (TFPI) from different cell lines shows up to 15-fold differences in the ratio of anticoagulant to chromogenic activity. The anticoagulant activity was dependent on the purification procedure used and it was possible to isolate two fractions of recombinant TFPI. Only one of these fractions showed anticoagulant activity comparable with TFPI from normal human plasma, and Western blotting showed that the low-activity fraction did not react with an antibody raised against a peptide of TFPI located near the C-terminal. Analysis by mass spectroscopy of peptides from V8 protease digests showed that C-terminal amino acids could only be identified from the high-activity form, while heterologous fragmentation had taken place in the form with low anticoagulant activity. Previously published studies on TFPI have been performed using material of low anticoagulant activity compared with plasma TFPI, and we suggest that these studies have been performed with material degraded in the C-terminus.
Similar articles
-
Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.Blood. 1992 Apr 15;79(8):2004-10. Blood. 1992. PMID: 1562726
-
Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients.Blood Coagul Fibrinolysis. 1991 Dec;2(6):713-21. doi: 10.1097/00001721-199112000-00004. Blood Coagul Fibrinolysis. 1991. PMID: 1799658
-
Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin.Blood Coagul Fibrinolysis. 1992 Apr;3(2):221-2. Blood Coagul Fibrinolysis. 1992. PMID: 1318759 No abstract available.
-
TFPI-dependent activities of protein S.Thromb Res. 2012 May;129 Suppl 2:S23-6. doi: 10.1016/j.thromres.2012.02.024. Epub 2012 Mar 15. Thromb Res. 2012. PMID: 22425215 Review.
-
The present status of tissue factor pathway inhibitor.Blood Coagul Fibrinolysis. 1992 Aug;3(4):439-49. Blood Coagul Fibrinolysis. 1992. PMID: 1420819 Review.
Cited by
-
Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation.J Exp Med. 1994 Jun 1;179(6):1847-54. doi: 10.1084/jem.179.6.1847. J Exp Med. 1994. PMID: 8195712 Free PMC article.
-
Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor.Biochem J. 1994 Jan 1;297 ( Pt 1)(Pt 1):131-6. doi: 10.1042/bj2970131. Biochem J. 1994. PMID: 8280090 Free PMC article.
-
Influences of lipid-modifying agents on hemostasis.Cardiovasc Drugs Ther. 1993 Nov;7(5):817-23. doi: 10.1007/BF00878936. Cardiovasc Drugs Ther. 1993. PMID: 8110626 Review.
-
TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain.Blood. 2014 Jun 19;123(25):3979-87. doi: 10.1182/blood-2014-01-551812. Epub 2014 Apr 16. Blood. 2014. PMID: 24740810 Free PMC article.
-
The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.J Clin Invest. 1995 Apr;95(4):1773-81. doi: 10.1172/JCI117855. J Clin Invest. 1995. PMID: 7706485 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous